Twist Bioscience Corporation TWST
Set alert
140.22 USD +11.18 +8.66%
As of Nov 3, 1:26 PM ET
130.22 Day range 141.62
23.30 52-week range 219.71
- YTD
- +342.04%
- 1 year
- +344.14%
- Open
- 130.35
- Prev close
- 129.04
- Mkt cap
- 9.30B
- Vol
- 1.09M
- Avg vol
- 2.32M
- EPS
- -2.23
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 130.22
- High
- 141.62
- Forward P/E
- -322.60
- Beta
- 2.22
- Short ratio
- 3.22
- Inst. own
- 117.41%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 12, 2026
- 50-d avg
- 153.11
- 200-d avg
- 89.02
- 1y target
- 168.25
6M chart
Events in this range
- May 4, 2026Earnings: -0.71; estimate -0.49; surprise -44.9%
- Aug 3, 2026Earnings: -0.56; estimate -0.50625; surprise -10.62%
- Sep 29, 2026Rating: Leerink Partners · Outperform → Outperform
- Oct 1, 2026Rating: Guggenheim · Buy → Buy
- Oct 7, 2026Rating: Barclays · Overweight → Overweight
- Oct 8, 2026Rating: Jefferies · — → Hold
- Oct 12, 2026Rating: Canaccord Genuity · Buy → Buy
- Oct 13, 2026Rating: TD Cowen · Buy → Buy
Signals (21)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Nov 2, 2026 | 1 day ago |
| SMA: Bearish | Oct 30, 2026 | 4 days ago |
| MACD: Buy Signal | Oct 28, 2026 | 6 days ago |
| SMA: Bullish | Oct 27, 2026 | 1 week ago |
| SMA: Bearish | Oct 15, 2026 | 2 weeks ago |
| MACD: Sell Signal | Oct 7, 2026 | 3 weeks ago |
| RSI: Overbought | Sep 24, 2026 | 1 month ago |
| RSI: Overbought | Sep 18, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 17, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 1, 2026 | 2 months ago |
| RSI: Overbought | Aug 19, 2026 | 2 months ago |
| RSI: Overbought | Aug 10, 2026 | 2 months ago |
| RSI: Overbought | Aug 5, 2026 | 3 months ago |
| MACD: Buy Signal | Aug 4, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 7, 2026 | 3 months ago |
| RSI: Overbought | Jun 24, 2026 | 4 months ago |
| RSI: Overbought | Jun 15, 2026 | 4 months ago |
| RSI: Overbought | Jun 3, 2026 | 5 months ago |
| MACD: Buy Signal | May 22, 2026 | 5 months ago |
| SMA: Bullish | May 20, 2026 | 5 months ago |
Newest 20 of 21.
Analyst view
Consensus: buy
Buy
Price target (mean) 168.25 +20.0% upside
Now 140.22
- Target (low)
- 45.00
- Target (mean)
- 168.25
- Target (high)
- 215.00
Ratings (0m) 13 9 buy · 3 hold · 1 sell
- Strong buy2
- Buy7
- Hold3
- Sell1
- Strong sell0
Recommendation trend
- This month 13
- 1 month ago 13
- 2 months ago 11
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.203 | -0.382 – -0.02 | -0.45 | +54.9% | 123.58M | +24.8% | 4 |
| Next quarter | -0.138 | -0.314 – -0.04 | -0.50 | +72.4% | 126.42M | +21.9% | 3 |
| Current year | -1.20 | -2.14 – -0.57 | -2.12 | +43.5% | 456.30M | +21.2% | 5 |
| Next year | -0.40 | -1.12 – 0.10 | -1.20 | +66.6% | 548.64M | +20.2% | 4 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 13, 2026 | TD Cowen | Maintained | Buy | Buy |
| Oct 12, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Oct 8, 2026 | Jefferies | Initiated | — | Hold |
| Oct 7, 2026 | Barclays | Maintained | Overweight | Overweight |
| Oct 1, 2026 | Guggenheim | Maintained | Buy | Buy |
| Sep 29, 2026 | Leerink Partners | Maintained | Outperform | Outperform |
| Sep 18, 2026 | BWS Financial | Maintained | Sell | Sell |
| Sep 17, 2026 | Leerink Partners | Maintained | Outperform | Outperform |
| Sep 9, 2026 | BWS Financial | Initiated | — | Sell |
| Sep 9, 2026 | UBS | Initiated | — | Neutral |
| Aug 5, 2026 | Piper Sandler | Maintained | Overweight | Overweight |
| Aug 4, 2026 | Baird | Maintained | Outperform | Outperform |
| Jul 14, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Jul 6, 2026 | Evercore ISI Group | Downgrade | Outperform | In-Line |
| Jun 29, 2026 | Guggenheim | Maintained | Buy | Buy |
| Jun 24, 2026 | Barclays | Maintained | Overweight | Overweight |
| Jun 15, 2026 | TD Cowen | Maintained | Buy | Buy |
| Jun 15, 2026 | Canaccord Genuity | Initiated | — | Buy |
| Jun 11, 2026 | Piper Sandler | Initiated | Overweight | Overweight |
| May 5, 2026 | Leerink Partners | Upgrade | Market Perform | Outperform |
| May 5, 2026 | Barclays | Maintained | Overweight | Overweight |
| May 5, 2026 | Guggenheim | Maintained | Buy | Buy |
| May 5, 2026 | Baird | Maintained | Outperform | Outperform |
| Apr 14, 2026 | Barclays | Maintained | Overweight | Overweight |
| Apr 6, 2026 | Evercore ISI Group | Maintained | Outperform | Outperform |
| Mar 30, 2026 | Guggenheim | Maintained | Buy | Buy |
| Feb 3, 2026 | Evercore ISI Group | Maintained | Outperform | Outperform |
| Feb 3, 2026 | Barclays | Maintained | Overweight | Overweight |
| Jan 26, 2026 | Guggenheim | Maintained | Buy | Buy |
| Jan 8, 2026 | TD Cowen | Maintained | Buy | Buy |